

Amendments to the Claims

The following Listing of Claims replaces all prior versions and listings of the claims in this application.

Listing of the Claims:

Claims 1-24 (Cancelled).

Claim 25 (Currently Amended) A group 2 allergen specific human IgE Fab having a heavy chain consisting of an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, ~~and/or~~ and a light chain consisting of an amino acid sequence as shown in SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.

Claim 26 (Currently Amended) A group 2 allergen specific human IgG comprising the variable regions of the IgE Fab of claim ~~45~~ 25.

Claim 27 (Previously Presented) The IgG according to claim 26, wherein the IgG is directed against Phl p 2.

Claim 28 (Currently Amended) A diagnostic reagent comprising the IgG according to claim 26, and/or the corresponding complete antibody, ~~and/or a modified version of the IgG and/or the antibody.~~

Claim 29 (Previously Presented) A diagnostic kit comprising the reagent according to claim 28.

Claim 30 (Currently Amended) The IgE Fab according to claim 45 25, wherein the IgE Fab is directed against Phl p 2.

Claim 31 (Currently Amended) The IgE Fab according to claim 45 25, wherein the IgE Fab is recombinantly produced.

Claim 32 (Currently Amended) A diagnostic reagent comprising the IgE Fab according to claim 45 25, and/or the corresponding complete antibody, ~~and/or a modified version of the Fab and/or the antibody.~~

Claim 33 (Previously Presented) A diagnostic kit comprising the reagent according to claim 32.

Claim 34 (Currently Amended) A vaccine against type I allergy, comprising the IgE Fab according to claim 45 25, and/or the corresponding complete antibody, ~~and/or a modified version of the Fab and/or the antibody.~~

Claim 35 (Currently Amended) A method for passive immunotherapy of type I allergy, comprising administering a Phl p 2-specific IgE Fab according to claim 45 25.

Claim 36 (Currently Amended) A method for diagnosing type I allergy, comprising contacting a sample with a Phl p 2-specific IgE Fab according to claim 45 25.

Claim 37 (Currently Amended) A method for environmental allergen detection, comprising contacting a sample with a Phl p 2-specific IgE Fab according to claim 45 25.

Claim 38 (Currently Amended) A method for standardization of allergen extract, comprising standardizing the allergen extract with a Phl p 2-specific IgE Fab according to claim 45 ~~25~~.

Claim 39 (Currently Amended) A group 2 allergen specific human IgE Fab having a heavy chain encoded by a nucleic acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and ~~and/or~~ a light chain encoded by the nucleic acid as shown in SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

Claim 40 (Currently Amended) A group 2 allergen specific human IgG comprising the variable regions of the IgE Fab of claim 46 ~~39~~.

Claim 41 (Currently Amended) The IgE Fab according to claim 46 ~~39~~, wherein the IgE Fab is directed against Phl p 2.

Claim 42 (Currently Amended) A diagnostic reagent comprising the IgE Fab according to claim 46 ~~39~~, and/or the corresponding complete antibody; ~~and/or a modified version of the Fab and/or the antibody.~~

Claim 43 (Previously Presented) A diagnostic kit comprising the reagent according to claim 42.

Claim 44 (Currently Amended) A vaccine against type I allergy, comprising the IgE Fab according to claim ~~46~~ 39, and/or the corresponding complete antibody, ~~and/or a modified version of the Fab and/or the antibody.~~

Claim 45 (Previously Presented) A group 2 allergen specific human IgE Fab having a heavy chain consisting of an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, and a light chain consisting of an amino acid sequence as shown in SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12, respectively.

Claim 46 (Previously Presented) A group 2 allergen specific human IgE Fab having a heavy chain encoded by a nucleic acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and a light chain encoded by the nucleic acid as shown in SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, respectively.